November 30, 2012—Legislation that aims to address drug shortages by exempting manufacturers from providing 340B discounts on certain pharmaceuticals has been introduced in the U.S. House. Rep. Bill Cassidy (R-La.), a member of the House Energy and Commerce Subcommittee on Health, introduced the Patient Access to Drugs in Shortage Act (H.R. 6611) late yesterday. … [Read more...]
GAO Asked to Study GPOs’ Possible Role in Drug Shortages
House Democrats' request spurred by meningitis outbreak linked to tainted drugsNovember 19, 2012—Six influential House Democrats have asked the Government Accountability Office (GAO) to investigate whether group purchasing organization (GPO) contracting practices have caused drug shortages that, in turn, have forced hospitals and other providers to rely on compounding pharmacies to obtain medicines at reasonable cost. The Nov. 15 request came amid … [Read more...]
Bill Carving Some Drugs Out of 340B Is Expected Soon
Certain generic injectable products would be exempt for up to 7 yearsNovember 16, 2012—Expectations are growing that a bill may be introduced in Congress soon that would exempt certain generic injectable drugs from 340B drug discounts for possibly up to seven years. Rep. Bill Cassidy (R-La.), a member of the House Energy and Commerce Subcommittee on Health, has drafted drug shortage legislation that includes the 340B discount exemption and … [Read more...]
Suit Filed Over Reduced-Price Vaccines Through 340B Prime Vendor
For-profit clinic says voluntary discounts for safety-net providers are unfairNovember 14, 2012—A private, for-profit immunization clinic in Las Vegas has filed a federal lawsuit seeking to stop GlaxoSmithKline (GSK) from selling vaccines to a Nevada local public health entity at voluntarily discounted prices negotiated by the 340B Prime Vendor Program (PVP). In an Oct. 25 complaint filed in federal district court in Las Vegas, The Vaccine Center … [Read more...]
Mylan to Issue Refunds for 340B Overcharges
Providers, meanwhile, begin receiving overcharge refunds from GSKNovember 7, 2012—Drug manufacturer Mylan will soon be mailing refunds to 340B providers for overcharges on all products sold by its Dey Pharma subsidiary from late 1994 through late 2006, according to an announcement on the Office of Pharmacy Affairs (OPA) home page. In its statement on the OPA Web site, Mylan said the need to provide refunds to 340B covered entities "arises … [Read more...]
OPA Activates 340B Disaster Flexibilities Policy for N.Y. and N.J.
Notice now on Web site lacks earlier discussion of patient eligibilityNovember 7, 2012—The Office of Pharmacy Affairs (OPA) significantly revised its 340B "flexibilities during disasters" policy yesterday just four days after activating it in New York and New Jersey in the wake of Hurricane Sandy. Under the revised policy, it is no longer clear whether OPA will give hospitals, health centers, and other providers affected by the storm … [Read more...]
HRSA Requests Comments on 340B Reporting Requirements
Input Requested on Audits and Dispute Resolution Burdens, Due by Dec. 25October 26, 2012—HRSA has issued a request for comment on proposed forms relating to audits and dispute resolution. Earlier this year, HRSA launched a number of audits of covered entities to determine if they are in compliance with program requirements. … [Read more...]